Compass Pathways prices $150 million public offering at $8 per share

Compass Pathways plc (NASDAQ: CMPS) announced the pricing of its public offering of 17.5 million American Depositary Shares at $8.00 per ADS. The biotechnology company also offered pre-funded warrants to purchase up to 1.25 million ADSs at $7.9999 per warrant to certain institutional investors.

The company granted underwriters a 30-day option to purchase up to an additional 2.8 million ADSs at the public offering price. The offering is expected to close on or about February 20, 2026, subject to customary closing conditions.

Gross proceeds from the offering are expected to reach $150 million before underwriting discounts and other expenses. Compass Pathways plans to use the net proceeds to fund ongoing COMP005 and COMP006 Phase 3 trials, its Phase 2b/3 trial of COMP360 in PTSD, commercial readiness activities, and general corporate purposes.

Jefferies, TD Cowen, Cantor and Stifel serve as joint book-runners for the offering, while H.C. Wainwright & Co. acts as lead manager. LifeSci Capital serves as the company's financial advisor.

The securities are being offered under a shelf registration statement that became effective on May 7, 2025. Compass Pathways is developing COMP360, an investigational synthetic psilocybin treatment that has received Breakthrough Therapy designation from the FDA for treatment-resistant depression.

You May Also Be Interested In

• Jade Biosciences announces underwritten public offering of common stock
• FDA grants fast track status to Verastem's lung cancer drug VS-7375
• Bitmine Immersion Technologies plans $300 million preferred stock offering